Posterior Vitreous Detachment

Posterior vitreous detachment (PVD) falls within the category of vitreoretinal interface disorders—conditions affecting the boundary between the vitreous and the retina. To understand PVD, it helps to know a little about the vitreous itself. The vitreous humor is the clear, jelly-like substance that fills about 80% of the interior of the eye, between the lens and the retina. It consists of roughly 99% water, held together by a delicate scaffolding of collagen fibers and a sugar-based molecule called hyaluronic acid. In youth, this gel is transparent, tightly organized, and firmly attached to the inner surface of the retina. Over time, the collagen scaffold degrades, the hyaluronic acid separates from the collagen network, and the gel gradually liquefies from within. This aging process eventually leads to PVD—the separation of the outer layer of the vitreous from the retina. Vitreoretinal interface disorders range in clinical significance from entirely benign changes that require only reassurance to sight-threatening complications requiring urgent surgical intervention.

Posterior vitreous detachment is the separation of the gel-like vitreous from the light-sensitive inner lining of the back of the eye—the retina. More precisely, the dense outer layer of the vitreous (called the posterior vitreous cortex) separates from the internal limiting membrane (ILM), a thin basement membrane on the retinal surface. PVD is not a disease in the traditional sense—it is a natural, nearly universal part of the normal aging of the eye. By age 70, approximately 80% of healthy individuals have some degree of posterior vitreous separation, and about 50% have complete PVD. Most people who experience PVD go through an adjustment period of floaters and occasional flashing lights lasting weeks to months, and then return entirely to their baseline quality of life. However, in a minority of cases—particularly when the vitreous remains partially and focally attached to the retina during the separation process—PVD can trigger sight-threatening complications including retinal tears, retinal detachment, and macular damage that require urgent treatment.

Posterior vitreous detachment results from two interrelated processes that progressively weaken the structural integrity of the vitreous gel and its attachment to the retina, both driven primarily by aging.

The first process is vitreous syneresis—liquefaction of the vitreous gel. With aging, the molecular interaction between the collagen fibrils and hyaluronic acid that normally keeps the gel uniformly structured breaks down. Hyaluronic acid separates from the collagen network and pools, creating pockets of liquid within the gel (called lacunae) that first appear in the central vitreous, anterior to the macula. These liquid pockets gradually grow and merge. By age 80, approximately half of the total vitreous volume has liquefied. The second process is degradation of the collagen scaffold itself—the type II and type IX collagen fibrils that give the vitreous its structure fragment into smaller pieces, concentrating the remaining gel at the outer surface (the posterior vitreous cortex). The exact molecular trigger for this fibril breakdown remains incompletely understood.

The final mechanical event that produces acute PVD typically occurs when sufficient vitreoretinal adhesion has been weakened and sufficient liquefied vitreous has accumulated: a small defect develops in the posterior vitreous cortex, and liquid vitreous passes through this defect into the space between the cortex and the retina. The cortex then collapses forward (anteriorly), detaching from the retinal surface in a wave from the posterior pole outward. When this occurs rapidly and the vitreous remains focally adherent to the retinal surface at points of abnormally strong adhesion, mechanical traction is transmitted to the retina—which can cause retinal tears, vitreous hemorrhage, or macular damage. Several conditions accelerate this liquefaction process and increase the risk of these complications:

• High myopia: The elongated eye of a severely myopic person has greater vitreous volume and structurally altered collagen, producing earlier and more rapid liquefaction. Complete PVD occurs in 54% of highly myopic adults aged 50 to 59, compared to 14% of non-myopic adults in the same age group.
• Cataract surgery: Surgical removal of the natural lens (phacoemulsification) disrupts the anterior vitreous structure and accelerates the liquefaction cascade, advancing the timing of PVD after surgery.
• Intraocular inflammation (uveitis): Inflammatory enzymes in the vitreous cavity break down the collagen matrix, accelerating degeneration.
• Aphakia (no natural lens): Loss of the crystalline lens removes a key structural support for the anterior vitreous.
• Ocular trauma: Direct mechanical force disrupts vitreoretinal adhesions and can initiate the separation process acutely.
• Hereditary vitreoretinal disorders: Stickler syndrome (caused by mutations in collagen genes including COL2A1, COL11A1, COL11A2, and others) produces structurally defective vitreous from birth, causing early-onset PVD and carrying a lifetime rhegmatogenous retinal detachment risk of up to 65%. Wagner syndrome (VCAN/versican mutation) and Marfan syndrome (FBN1 mutation) cause similar accelerated vitreous degeneration and early PVD.

Posterior vitreous detachment is primarily a condition of aging and becomes nearly universal by the eighth decade of life. The following factors increase the likelihood of earlier-onset PVD or a higher risk of sight-threatening complications during or after the separation.

• Advanced age: the primary risk factor. Nearly all healthy individuals have some mid-peripheral vitreoretinal separation by age 40, and approximately 50% have complete PVD by age 70. The process is progressive and universal.
• Female sex (postmenopausal): Estrogen loss weakens connective tissue throughout the body, including vitreous collagen support. PVD occurs at younger ages in women, and women predominate in the populations with vitreomacular traction and macular holes.
• High myopia: a strongly quantifiable risk factor. Complete PVD is found in 6.7% of highly myopic adults aged 20 to 29 versus 0% of non-myopic adults in the same age range. By ages 50 to 59, the rates are 54% versus 14%. High myopia also increases the risk of anomalous (vitreoschisis) PVD patterns and the associated complications.
• Prior cataract surgery (pseudophakia): Anterior vitreous disruption from cataract surgery accelerates the liquefaction of the posterior vitreous. In a large registry study of more than three million eyes, the risk of retinal detachment after cataract surgery was 0.21% within one year.
• Hereditary connective tissue disorders: Stickler syndrome, Wagner syndrome, and Marfan syndrome all involve genetically defective vitreous collagen, producing early-onset severe vitreous degeneration and significantly elevated retinal detachment risk.
• Ocular trauma and uveitis: Each accelerates vitreous liquefaction through distinct mechanisms and increases the risk of early or complicated PVD.
• Presenting symptom profile: Certain symptoms at initial presentation significantly predict the risk of a concurrent retinal tear. Having more than 10 floaters carries an odds ratio of 19.8 for retinal tears. When flashes and floaters occur simultaneously, the tear risk is approximately 20%—compared to 5% for flashes alone or 16.5% for floaters alone. Vitreous hemorrhage at presentation is associated with approximately 30% retinal tear risk.
• Fellow-eye epiretinal membrane (ERM): Having an epiretinal membrane in the other eye is associated with an odds ratio of 11.9 for ERM development in the affected eye after PVD.

Posterior vitreous detachment as a physiologic aging process cannot be prevented. However, several steps can reduce the risk of its sight-threatening complications:

• Use protective eyewear: Polycarbonate safety glasses during contact sports, construction work, and other high-risk activities reduce the risk of traumatic vitreous disruption and associated complications.
• Myopia control in children: Slowing axial elongation in myopic children through orthokeratology, low-dose atropine (0.01–0.05%) eye drops, or multifocal contact lenses delays the onset of the severe myopia that dramatically accelerates vitreous degeneration and early PVD.
• Control ocular inflammation: Prompt treatment of uveitis and other intraocular inflammatory conditions with appropriate anti-inflammatory medications reduces the enzymatic vitreous degradation that accelerates PVD and its complications.
• Presurgical counseling: Patients with high myopia or lattice degeneration who are planning cataract surgery should receive specific retinal detachment risk counseling before the procedure.
• Genetic counseling: Families with known Stickler syndrome, Wagner syndrome, or Marfan syndrome should receive genetic counseling, carrier testing, and regular retinal surveillance with a vitreoretinal specialist experienced in these conditions.

For patients with uncomplicated PVD who have been examined and cleared of retinal tears, the remaining symptoms are caused by the vitreous opacities themselves. Persistent, bothersome floaters after PVD are common. Epiretinal membrane—a thin layer of fibrocellular scar tissue on the macular surface that can form in the months following PVD—develops in approximately 35% of eyes within 12 months of acute PVD onset and may cause central visual distortion (metamorphopsia) or reduced acuity. Patients should be alert to any new or worsening central visual distortion in the months following PVD and report it promptly. Any new increase in floaters, new flashing lights, or new visual field changes in a previously stable PVD eye should also be re-evaluated promptly, as a small percentage of eyes develop a retinal tear on follow-up even when none was found at the initial examination.

Posterior vitreous detachment is diagnosed by an ophthalmologist, typically following a patient’s report of new floaters or flashing lights. The diagnosis is primarily clinical—made by direct examination of the vitreous and retina—with imaging used for confirmation, staging, and detecting complications. At the initial evaluation, two priorities take precedence: confirming the presence and stage of PVD, and determining whether a retinal tear or retinal detachment has occurred, which requires the same-day decision about urgent laser treatment or referral to a retinal surgeon.

• Dilated fundus examination with indirect ophthalmoscopy: the gold standard first-line examination for symptomatic PVD. After the pupil is dilated with eye drops, the ophthalmologist examines the entire retina, including the extreme periphery, using a condensing lens and a bright light source. This identifies the Weiss ring (confirming complete PVD), detects peripheral retinal tears, localizes vitreous hemorrhage, and assesses the extent of the separation.
• Slit-lamp biomicroscopy with 90D or 78D condensing lens: a magnified examination of the vitreous and posterior pole. The posterior hyaloid membrane (the separated vitreous cortex) has a sensitivity of 89.8% for PVD detection on slit-lamp examination. The Weiss ring has a sensitivity of 79.7%.
• Spectral-domain optical coherence tomography (SD-OCT): the gold standard for characterizing the vitreoretinal interface and diagnosing VMA, VMT, and macular holes. SD-OCT provides high-resolution cross-sectional images of every retinal layer and can precisely measure the width and depth of any remaining vitreous attachment to the fovea, detect intraretinal cysts and subretinal fluid caused by VMT, identify ellipsoid zone disruption indicating photoreceptor damage, and measure macular hole dimensions for treatment planning. It also detects vitreous hyperreflective dots that may be associated with peripheral retinal breaks. SD-OCT is the essential tool for monitoring VMA over time and for staging macular hole size.
• B-scan ultrasonography: used when the vitreous hemorrhage or other opacity within the eye prevents direct visualization of the retina. B-scan produces a real-time cross-sectional ultrasound image of the eye, detecting the echogenic membrane of a detached vitreous with 90.2% specificity for complete PVD and identifying any underlying retinal detachment.

All symptomatic patients with acute-onset PVD should have a follow-up dilated retinal examination at approximately six weeks after the initial visit, even when no retinal tear was found at the first examination. Studies show that approximately 3–4% of eyes with an initially uncomplicated PVD develop a new retinal tear at the follow-up visit. Patients should also return between scheduled visits for any new increase in floaters, new flashing lights, or any curtain or shadow in the visual field.

When partial PVD produces vitreomacular traction (VMT) that is distorting the fovea, several treatment approaches are available depending on the size of the attachment, the severity of the structural changes, and whether the traction has progressed to a macular hole. For many cases of VMT—particularly focal attachments with limited foveal distortion—watchful waiting is appropriate, because approximately 12–40% of focal VMTs resolve spontaneously without treatment as the vitreous completes its natural separation. Spectral-domain OCT, every three months, monitors the attachment for resolution or progression. When treatment is required, ocriplasmin (Jetrea®), the only U.S. Food and Drug Administration (FDA)-approved pharmacological treatment for vitreomacular adhesion and traction, offers a nonsurgical option. Ocriplasmin is a recombinant enzyme—a modified version of the naturally occurring protease plasmin—that is injected into the vitreous cavity in a single intravitreal injection. It dissolves the protein bonds (specifically fibronectin and laminin) anchoring the vitreous to the fovea, facilitating pharmacologic induction of complete PVD. In the pivotal Phase 3 MIVI-TRUST trials, ocriplasmin resolved VMA in 26.5% of treated eyes compared to 10.1% with placebo, and was more effective for focal than broad attachments and for eyes without a concurrent epiretinal membrane. Side effects include transient vitreous floaters, temporary visual disturbance, and, in some patients, electroretinographic changes; patients should be counseled about the possibility of a brief worsening of visual symptoms in the days following injection before improvement occurs. When VMT has progressed to a full-thickness macular hole, or when pharmacologic or watchful management has failed, pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling and gas tamponade is the standard surgical treatment, achieving anatomical closure of the hole in 85–100% of cases. A detailed description of macular hole surgery is provided in the Macular Hole page.

For the majority of people who experience PVD, the condition is a self-limited, manageable event. The acute phase—weeks of prominent floaters and occasional flashing lights—is genuinely disorienting and can be frightening, particularly before the diagnosis is confirmed. Having the ophthalmological examination that rules out a retinal tear, and receiving a clear explanation of what is happening inside the eye and what to expect, is consistently cited by patients as the most important step in coping with acute PVD. After that initial evaluation, most people find that the floaters become less intrusive over weeks to months as the brain adapts, and that life returns entirely to normal within six months.

The most important ongoing responsibility for anyone who has had PVD is to know the warning signs that require a same-day return call to the ophthalmologist: a dramatic increase in floaters, any new curtain or shadow in the vision, reddish or cloudy vision, or both flashes and floaters occurring simultaneously. These symptoms in a previously stable PVD eye need to be evaluated the same day—not watched for a few days, and not attributed to the known PVD without re-examination. In the months after the acute episode, any new central visual distortion (such as straight lines appearing wavy when viewed with the affected eye) should prompt rapid evaluation for epiretinal membrane, which develops in approximately one-third of eyes within the first year after PVD. Regular annual dilated eye examinations going forward provide ongoing monitoring and peace of mind.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of posterior vitreous detachment and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.